Can integration of Alzheimer’s plasma biomarkers with MRI, cardiovascular, genetics, and lifestyle measures improve cognition prediction?
Robel K Gebre(Mayo Clinic), Prashanthi Vemuri(Mayo Clinic in Arizona), Jonathan Graff‐Radford(Mayo Clinic in Arizona), Maria Vassilaki(Mayo Clinic in Florida), Jeffrey L. Gunter(Mayo Clinic), Ekaterina I. Hofrenning(Mayo Clinic in Florida), Scott A. Przybelski(Mayo Clinic in Florida), Vijay K. Ramanan(Mayo Clinic), Mary M. Machulda(Mayo Clinic), Alicia Algeciras‐Schimnich(Mayo Clinic), Ronald C. Petersen(Mayo Clinic), Aivi T. Nguyen(Mayo Clinic), Timothy G. Lesnick(Mayo Clinic), David S. Knopman(Mayo Clinic), Val J. Lowe(Mayo Clinic in Arizona), Sheelakumari Raghavan(Mayo Clinic), Clifford R. Jack(Mayo Clinic)
Cited by 6
Related Papers
Mild cognitive impairment as a diagnostic entity
|Journal of Internal Medicine|2004|7.8k
Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment
|Journal of Internal Medicine|2004|5k
Practice parameter: Early detection of dementia: Mild cognitive impairment (an evidence-based review) [RETIRED]
|Neurology|2001|2.1k
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
|Alzheimer s & Dementia|2024|2.1k
Primary age-related tauopathy (PART): a common pathology associated with human aging
|Acta Neuropathologica|2014|1.5k